Survival of 86,690 patients with thyroid cancer: A population-based study in 29 European countries from EUROCARE-5

Maso, Luigino Dal; Pacini, Furio; Dijk, Boukje A. C. van; Larrañaga, Nerea; Rubió‐Casadevall, Jordi; Kowalska, Aldona; Virdone, Saverio; Hackl, Monika; Zielonke, N.; Eycken, E. Van; Henau, Kris; Valerianova, Z.; Dimitrova, Nadya; Šekerija, Mario; Dušek, Ladislav; Zvolský, Miroslav; Storm, Hans; Engholm, Gerda; Mägi, Margit; Aareleid, Tiiu; Malila, Nea; Seppä, Karri; Velten, Michel; Guizard, A.V.; Faivre, Jean; Woronoff, Anne Sophie; Trétarre, Brigitte; Bossard, Nadine; Uhry, Zoé; Colonna, Marc; Molinié, F.; Bara, Simona; Schvartz, Claire; Lapôtre-Ledoux, Bénédicte; Grosclaude, Pascale; Stabenow, Roland; Luttmann, Sabine; Eberle, Andrea; Brenner, Hermann; Nennecke, Alice; Engel, Jutta; Schubert-Fritschle, Gabriele; Heidrich, Jan; Holleczek, Bernd; Katalinic, Alexander; Jonasson, Jón G.; Tryggvadóttír, Laufey; Comber, Harry; Mazzoleni, Guido; Bulatko, A.; Buzzoni, Carlotta; Giacomin, Adriano; Sardo, Antonella Sutera; Mazzei, A.; Ferretti, Stefania; Barchielli, Alessandro; Caldarella, Adele; Gatta, Gemma; Sant, Milena; Amash, H.; Amati, C.; Baili, Paolo; Berrino, Franco; Bonfarnuzzo, S.; Botta, Laura; Capocaccia, Riccardo; Salvo, Francesca Di; Foschi, Roberto; Margutti, C.; Meneghini, Elisabetta; Minicozzi, Pamela; Trama, Annalisa; Serraino, Diego; Zucchetto, Antonella; Angelis, Roberta De; Caldora, M.; Carrani, E.; Francisci, Silvia; Mallone, Sandra; Pierannunzio, Daniela; Roazzi, Paolo; Rossi, Silvia; Santaquilani, Mariano; Tavilla, Andrea; Pannozzo, Fabio; Busco, Susanna; Filiberti, Rosa Angela; Vercelli, Marina; Ricci, Paolo; Autelitano, M.; Spagnoli, Gianbattista; Crimi, Claudia; Fusco, Mario; Vitale, Maria Francesca; Usala, M.; Vitale, Flora; Ravazzolo, Barbara; Michiara, Maria; Tumino, Rosario; Mangone, Lucìa; Vicentini, Massimo; Falcini, Fabio; Iannelli, A.; Sechi, O.; Cesaraccio, Rosaria; Piffer, Silvano; Madeddu, A; Tisano, F.; Maspero, S.; Fanetti, Anna Clara; Zanetti, Roberto; Rosso, Stefano; Candela, P.; Scuderi, T.; Stracci, Fabrizio; Rocca, Andrea; Tagliabue, Giovanna; Contiero, Paolo; Rugge, Massimo; Tognazzo, S; Pildava, Santa; Smailytė, Giedrė; Calleja, Neville; Agius, Dominic; Johannesen, Tom Børge; Rachtan, Jadwiga; Góźdż, Stanisław; Mężyk, Ryszard; Błaszczyk, Jerzy; Bębenek, Marek; Bielska–Lasota, Magdalena; Lacerda, G. Forjaz de; Bento, Maria José; Castro, Clara; Miranda, Ana; Mayer-da-Silva, A.; Diba, C. Safaei; Primic-Žakelj, Maja; Errezola, M.; Bidaurrazaga, J.; García, J.M. Díaz; Marcos-Navarro, A.I.; Marcos‐Gragera, Rafael; Font, A. Izquierdo; Yuste-Sánchez, María José; Molina, Esther; Navarro, Carmen; Chirlaque, María Dolores; Moreno‐Iribas, Conchi; Ardanaz, Eva; Galcerán, Jaume; Carulla, Marià; Lambe, Mats; Khan, S.; Mousavi, M.; Bouchardy, Christine; Usel, M.; Frick, Harald; Lorez, Matthias; Ess, Silvia; Herrmann, Christian; Bordoni, Andrea; Spitale, Alessandra; Konzelmann, Isabelle; Visser, Otto; Ho, Vincent K.Y.; Otter, Renée; Coleman, Michael P.; Allemani, Claudia; Rachet, Bernard; Rashbass, Jem; Broggio, John; Verne, Julia; Gavin, Anna; Donnelly, David; Brewster, David H.; Huws, Dyfed Wyn; White, C.

doi:10.1016/j.ejca.2017.02.023

Cited by 83 publications

(68 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The incidence of thyroid cancer has increased in many countries during the past decade and this is due mainly to an improvement achieved in detection methods [1,2]. Most cases are of the differentiated thyroid carcinoma and many patients undergo radioiodine remnant ablation (RRA) to eliminate the residual normal thyroid tissue after total thyroidectomy (TT) or near TT (NTT).…”

Section: Introductionmentioning

confidence: 99%

Low-Dose Radioiodine Ablation in Patients with Low-Risk Differentiated Thyroid Cancer

et al. 2018

View full text Add to dashboard Cite

Aim: Based on the response criteria of the 2015 American Thyroid Associations guidelines, our objectives were to determine the response rate when using a low dose of 131-I GBq in patients with low-risk differentiated thyroid cancer (LRDTC) and the influence of clinical and analytical variables on the prediction of complete response. Methods: We performed a multicentre and longitudinal study, including patients who were operated for LRDTC and who underwent radioiodine remnant ablation with a low-dose of 131-I. All patients were assessed at 6–12 months, and their status was classified as complete (excellent response) or incomplete response (structural incomplete, biochemical incomplete or indeterminate response). Various factors including age, gender, histology, tumour focality and size, stage, time from surgery to treatment, type of thyroid-stimulating hormone (TSH) stimulation, preablation serum thyroglobulin (pTg), antiTg antibodies (pAntiTgAb) and TSH (pTSH) levels were also analysed in order to predict the complete response rate. Results: Of 108 patients, 79.6% achieved complete response and the remaining showed incomplete response (2.9, 5.5 and 12% due to biochemical incomplete, structural incomplete and indeterminate response respectively). Six patients received a new dose of 131-I. Tumour size and pAntiTgAb were the only factors related to therapeutic response (p = 0.03 and p < 0.01, respectively). However, pAntiTgAb was the only independent factor related to complete response. Patients with complete response showed lower pTg than those with incomplete response (5.1 ± 12.9 vs. 11.2 ± 25 ng/mL) although without statistical significance (p = 0.14). There was no significant difference in the response rate depending on the thyrotropin stimulation methods. Conclusions: A low dose of 131-I was sufficient for reaching a complete response at 6–12 months of follow-up in the majority of patients with LRDTC. Tumour size and pAntiTgAb variables were related to therapeutic response.

show abstract

Section: Introductionmentioning

confidence: 99%

Low-Dose Radioiodine Ablation in Patients with Low-Risk Differentiated Thyroid Cancer

et al. 2018

View full text Add to dashboard Cite

show abstract

“…To evaluate the efficacy of RAIT, differences in the response to initial therapy and DFS as well as OS between the two groups were estimated. Given the generally good prognosis of PTCs, it is not sufficient to assess clinical outcomes using mortality alone . A recent study analysing data from the Surveillance, Epidemiology and End Results cancer registry and an institutional database reported an improved 10‐year relative survival rate of thyroid cancer over time .…”

Section: Discussionmentioning

confidence: 99%

“…Given the generally good prognosis of PTCs, it is not sufficient to assess clinical outcomes using mortality alone. [21][22][23][24] A recent study analysing data from the Surveillance, Epidemiology and End Results cancer registry and an institutional database reported an improved 10-year relative survival rate of thyroid cancer over time. 22 Several studies have proposed DRS, using the response to initial therapy, to evaluate an individual's risk of recurrence and mortality and to guide individualized management of PTC patients.…”

Section: Discussionmentioning

confidence: 99%

Impact of delayed radioiodine therapy in intermediate‐/high‐risk papillary thyroid carcinoma

Kim

Han

Jeon

et al. 2019

Clinical Endocrinology

View full text Add to dashboard Cite

Objective It remains unclear whether the time interval between total thyroidectomy and radioactive iodine therapy (RAIT) affects clinical outcomes in papillary thyroid carcinoma (PTC). Therefore, we evaluated the impact of timing of the first post‐thyroidectomy RAIT in intermediate‐to‐high‐risk PTC. Design and Patients This retrospective propensity score‐matched cohort study included 720 PTC patients who received RAIT for <90 or 90‐180 days (early and delayed groups, n = 360 each) after thyroidectomy. Responses to therapy, disease‐free survival (DFS) and overall survival (OS) were compared between the two groups. Results After matching, the baseline characteristics of the 360 patients in each group were similarly adjusted. Within the first 2 years after initial therapy, the number of patients classified into excellent, indeterminate, biochemical incomplete and structural incomplete response categories were 221 (61%), 74 (21%), 39 (11%) and 26 (7%) in the early group, and 204 (57%), 73 (20%), 59 (16%) and 24 (7%) in the delayed group, respectively. There was no significant difference in response to therapy between the two groups (P = 0.183). During the median follow‐up of 8.6 years, there was no significant difference in DFS (P = 0.060) and OS (P = 0.400) curves between the two groups. Delayed RAIT was not significantly associated with worse DFS (HR = 1.3, 95% CI 0.9‐1.8, P = 0.061) or OS (HR = 1.5, 95% CI 0.6‐3.4, P = 0.388). Conclusions Delaying the first RAIT until 180 days after total thyroidectomy had no impact on restaging, recurrence and mortality in intermediate‐to‐high‐risk PTC.

show abstract

“…Although, it is one of the most common cancer among endocrine malignancies accounting for more than 95% of new cases in the United States [2,3], according to American Cancer Society, thyroid cancer in the United States in 2019 is estimated to be about 53,070 new cases (40,260 in men and 37,810 in woman), and more than 2000 people will die from the disease [3]. As well as in the rest of the world, the incidence of thyroid cancer has increased threefold over the past 30 years and is expected to increase by 50-60% between 2010 and 2020 [3][4][5]. The increase in thyroid cancer incidence rates could be explained by thyroid ultrasound screening with improved technical performance of the equipment, as well as better access to medical examination [1,6].…”

Section: Introductionmentioning

confidence: 99%

Liquid Biopsy in Patients with Thyroid Carcinoma

Fridrihsone¹,

Āboliņš²,

Vanags³

et al. 2019

Liquid Biopsy

View full text Add to dashboard Cite

Thyroid cancer is a comparatively rare tumor, which affects 1-5% of women and approximately 2% of men, although it is the most common endocrine malignancy worldwide. Furthermore, the incidence of thyroid cancer has been increasing remarkably in the last decades. Currently, diagnosis of thyroid cancer mainly is based on cytological criteria. Although fine needle aspiration is a minimally invasive procedure, complications can occur. Correct diagnosis is mandatory to select patients for surgical intervention and to determine appropriate extent of operation. Overdiagnosis and the associated unnecessary surgery should be avoided as it might also lead to complications. Therefore it is important to practice noninvasive methods not only for early diagnosis of thyroid cancer but also for estimation of prognosis. Liquid biopsy is a promising, noninvasive method that can provide detection of circulating tumor cells (CTCs) as well as circulating nucleic acids such as DNA, mRNA, and microRNA in a blood sample. The aim of the chapter is to highlight the efficacy of liquid biopsy for diagnosis and prognosis of thyroid cancer. The chapter will represent a comprehensive literature review based on recent PubMed publications (mainly 2012-2018).

show abstract

Survival of 86,690 patients with thyroid cancer: A population-based study in 29 European countries from EUROCARE-5

Cited by 83 publications

References 36 publications

Low-Dose Radioiodine Ablation in Patients with Low-Risk Differentiated Thyroid Cancer

Low-Dose Radioiodine Ablation in Patients with Low-Risk Differentiated Thyroid Cancer

Impact of delayed radioiodine therapy in intermediate‐/high‐risk papillary thyroid carcinoma

Liquid Biopsy in Patients with Thyroid Carcinoma

Contact Info

Product

Resources

About